---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-079156"
form_type: "8-K"
ticker: null
cik: "0001641640"
company_name: "Nabriva Therapeutics plc"
filed_at: "2023-07-07T23:59:59+00:00"
generated_at: "2026-06-13T11:04:27.933013+00:00"
event_type: "leadership"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Nabriva Therapeutics CFO and interim CEO depart; restructuring consultants take over

## Summary
- CFO Daniel Dolan separated June 30, 2023; interim CEO/GC J. Christopher Naftzger separated July 7, 2023.
- Both executives receive 12 months base salary, COBRA premium payments, 100% target bonus, accelerated equity vesting.
- H. Michael Hogan appointed CEO and Dave Maggio appointed CFO effective July 7 and June 30 respectively, via Armanino LLP consulting agreement.
- Hogan and Maggio are partners/directors at Armanino, a restructuring firm; consulting fees $425-$650/hr and $375-$495/hr respectively.
- Appointments part of Cash Preservation Plan to wind down operations; consulting agreements expire Dec 31, 2023.

## SEC filing metadata
- accession: 0001104659-23-079156
- form_type: 8-K
- cik: 0001641640
- company_name: Nabriva Therapeutics plc
- filed_at: 2023-07-07T23:59:59+00:00
- event_type: leadership
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1641640/000110465923079156/0001104659-23-079156-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1641640/000110465923079156/tm2320799d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-079156
- JSON: https://secwatch.observer/filing/0001104659-23-079156.json
- Plain text: https://secwatch.observer/filing/0001104659-23-079156.txt

## Key facts
- Executive change
  J. Christopher Naftzger departed as Interim Chief Executive Officer, General Counsel and Secretary at Nabriva Therapeutics plc.
  - Action: separated
  - Role: Interim Chief Executive Officer, General Counsel and Secretary
  source text: and J. Christopher Naftzger, the Company’s Interim Chief Executive Officer, General Counsel and Secretary, entered into a Separation and Release of Claims Agreement with Nabriva Therapeutics US, Inc., a wholly-owned subsidiary of the Company, providing for their separation from employment with the Company effective June 30, 2023 (the “Dolan Separation Date”), in the case of Mr. Dolan, and July 7, 2023, in the case of Mr. Naftzger.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1641640/000110465923079156/0001104659-23-079156-index.htm
- Executive change
  Daniel Dolan departed as Chief Financial Officer at Nabriva Therapeutics plc.
  - Action: separated
  - Role: Chief Financial Officer
  source text: each of Daniel Dolan, the Company’s Chief Financial Officer, and J. Christopher Naftzger, the Company’s Interim Chief Executive Officer, General Counsel and Secretary, entered into a Separation and Release of Claims Agreement with Nabriva Therapeutics US, Inc., a wholly-owned subsidiary of the Company, providing for their separation from employment with the Company effective June 30, 2023 (the “Dolan Separation Date”), in the case of Mr. Dolan, and July 7, 2023, in the case of Mr. Naftzger.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1641640/000110465923079156/0001104659-23-079156-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.